Canine Hemangiosarcoma


Dr. Mason's lab is currently recruiting dogs for a novel clinical trial using immunotherapy to treat canine hemangiosarcoma.

Hemangiosarcoma is a common, aggressive cancer that arises from the cells that line blood vessels. Common sites of occurrence include the spleen, liver, and the right side of the heart.

The current standard of care for hemangiosarcoma that occurs in the spleen is surgical removal of the spleen followed by chemotherapy. Unfortunately despite surgery and chemotherapy, the disease usually spreads and most dogs succumb to their disease within 6-12 months of diagnosis.

Current Hemangiosarcoma Clinical Trials

Safety And Effectiveness Of Antibody Therapy For Dogs With Splenic Hemangiosarcoma

This trial evaluates the safety and effectiveness of an antibody therapy designed to inhibit VEGF and delay or prevent spread of hemangioscarcoma after surgery

cancer active Mason hemangiosarcoma Mason Cancer Studies Mason Active immunotherapy hemangiosarcoma canine hemangiosarcoma canine cancer cancer active